Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 84 results for infliximab

  1. Secukinumab for treating moderate to severe plaque psoriasis (TA350)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA350

  2. Psoriasis (QS40)

    This quality standard covers assessing and managing psoriasis in adults, young people and children. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    6 August 2013
    View quality statements

    Sections for QS40

  3. Upadacitinib for treating moderate rheumatoid arthritis (TA744)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    10 November 2021
    View recommendations

    Sections for TA744

  4. NICE agreed that further research would be of value to investigate factors which can predict the likelihood of rapid progression of disease and response to treatment with biological DMARDs. Factors to investigate include:- persistent elevation of inflammatory markers (such as C-reactive protein [CRP]) and- presence of erosions on X-ray and- positive for anti-citrullinated protein antibodies (ACPA).

    guidance details Comes from guidance Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for...

    Research recommendation
    Published
    15 March 2016

  5. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

    Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.

    Technology appraisal guidance
    Published
    26 August 2015
    View recommendations

    Sections for TA352

  6. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)

    Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative

    Diagnostics guidance
    Published
    2 October 2013
    View recommendations

    Sections for DG11

  7. Pouchitis: rifaximin (ESUOM30)

    Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

    Evidence summary
    Published
    25 March 2014

  8. Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA407

  9. Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

    Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.

    Technology appraisal guidance
    Published
    17 November 2021
    View recommendations

    Sections for TA747

  10. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)

    NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .

    Medtech innovation briefing
    Published
    4 December 2017

  11. Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)

    Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    6 September 2017
    View recommendations

    Sections for TA475

  12. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

    Evidence summary
    Published
    2 December 2015

  13. Infliximab for subacute manifestations of ulcerative colitis (TA140)

    This guidance has been updated and replaced by NICE technology appraisal guidance 329.

    Technology appraisal guidance
    Published
    23 April 2008

  14. Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Technology appraisal guidance
    Published
    28 May 2008

  15. Etanercept and infliximab for the treatment of psoriatic arthritis (TA104)

    This guidance has been replaced by NICE technology appraisal guidance 199.

    Technology appraisal guidance
    Published
    26 July 2006